ENTECAVIR 0.5MG TABLET (BARACLUDE) UP TO 44% OFF

Brand name - Baraclude 

Generic name - Entecavir 

Manufacturer - BMS India Pvt Ltd 

Salt composition - Entecavir (0.5 mg) 

Storage - Store at room temperature 

Dosage form - Oral 

Strength - 0.5 mg 

Packaging - Bottle of tablets 

Active ingredient - Entecavir 

Indication - treatment of chronic hepatitis B virus infection in adults and pediatric patients (2 years of age and older) 

Description  

Entecavir is a white to off-white powder. It is slightly soluble in water (2.4 mg/mL), and the pH of the saturated solution in water is 7.9 at 25° C ± 0.5° C. 

Baraclude film-coated tablets are for oral administration in strengths of 0.5 mg and 1 mg of entecavir. Baraclude 0.5 mg and 1 mg film-coated tablets contain the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, crospovidone, povidone, and magnesium stearate. The tablet coating contains titanium dioxide, hypromellose, polyethylene glycol 400, polysorbate 80 (0.5 mg tablet only), and iron oxide red (1 mg tablet only). Baraclude Oral Solution is available for oral administration as a ready-to-use solution containing 0.05 mg of entecavir per milliliter. Baraclude Oral Solution contains the following inactive ingredients: maltitol, sodium citrate, citric acid, methylparaben, propylparaben, and orange flavor. 

Baraclude is a Hepatitis B virus nucleoside analogue reverse transcriptase inhibitor, which is indicated for the treatment of chronic hepatitis B virus infection in adults and children, provided at least 2 years of age with an evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. It is not known that Baraclude is safe for children below 2 years of age. Baraclude will not cure HPV. It may decrease the ability of HPV to multiply.   

Pharmacodynamics  

Primary pharmacodynamics  

Entecavir is phosphorylated to the active triphosphate form (ETV-TP) by cellular nucleoside kinases. This was shown in different cell systems including infected hepatoma cell lines but the extent of phosphorylation of entecavir was dependent on cell-type. The triphosphate competes with the natural substrate, deoxyguanosine triphosphate (dGTP), of human HBV polymerase. In vitro studies on mechanism of action indicated that the three enzymatic activities of the viral polymerase were inhibited 1) priming activity, 2) reverse transcriptase activity resulting in first strand DNA synthesis and 3) DNA dependent DNA polymerase activity resulting in second-strand DNA synthesis.  

Secondary pharmacodynamics 

Entecavir did not show any significant potential for interactions in an in vitro receptor/channel ligand binding screen or enzyme-system assays at concentrations up to 100 µM. Unlike lamivudine or adefovir, ETV has no relevant activity against HIV-1 (EC50 > 10 µM).  

Pharmacodynamics drug interactions 

In vitro, co-administration of stavudine, didanosine, abacavir and zidovudine had no effect on HBV assays containing entecavir at the EC50. Entecavir at 0.8 to 4.2 x Cmax had no significant effects on EC50 values of stavudine, didanosine, abacavir, zidovudine, lamivudine and tenofovir in cells infected with three HIV strains.  

Usage of medicine 

Baraclude is used in the treatment of chronic Hepatitis B virus infection in adults and children provided at least 2 years of age. 

Alternate brands 

• X Vir 0.5 mg tablet 

• Cronivir tablet

• Entehep 0.5 mg tablet 

• Entavir 0.5 mg tablet